CA2210396A1 - Procede de detection et de traitement du cancer du sein - Google Patents

Procede de detection et de traitement du cancer du sein

Info

Publication number
CA2210396A1
CA2210396A1 CA002210396A CA2210396A CA2210396A1 CA 2210396 A1 CA2210396 A1 CA 2210396A1 CA 002210396 A CA002210396 A CA 002210396A CA 2210396 A CA2210396 A CA 2210396A CA 2210396 A1 CA2210396 A1 CA 2210396A1
Authority
CA
Canada
Prior art keywords
seq
ser
glu
gene
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002210396A
Other languages
English (en)
Inventor
Jeffrey T. Holt
Roy A. Jensen
David L. Page
Patrice S. Obermiller
Cheryl L. Robinson-Benion
Marilyn E. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2210396A1 publication Critical patent/CA2210396A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La présente invention concerne un procédé pour détecter et diagnostiquer un cancer du sein pré-invasif en identifiant, les gènes exprimés, de manière différentielle, dans les tissus cancéreux pré-invasifs du sein. Les gènes exprimés de manière différentielle peuvent être utilisés comme marqueurs génétiques pour indiquer la présence de tissus cancéreux pré-invasifs. Des techniques de prélèvement de tissus, effectuées au microscope, combinées à des techniques de visualisation différentielle ou de dosage différentiel de bibliothèques d'ADNc sont utilisées pour déterminer l'expression différentielle de gènes dans les premières étapes du cancer du sein. L'expression différentielle des gènes dans les tissus cancéreux préinvasifs du sein est confirmée par l'amplification de type transcriptase inverse - PCR, les dosages de protection de la nucléase et l'hybridation in situ de l'épithélioma dendritique dans l'ARN des tissus in situ et dans l'ARN des tissus témoins. La présente invention fournit également un procédé de dosage des composés qui induisent l'expression du gène BRCA1 dont le produit régule négativement la croissance cellulaire dans les cellules épithéliales mammaires normales et malignes. L'invention concerne également un procédé de thérapie génique utilisant ce gène.
CA002210396A 1995-01-17 1995-01-17 Procede de detection et de traitement du cancer du sein Abandoned CA2210396A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37379995A 1995-01-17 1995-01-17
US08/373,799 1995-01-17

Publications (1)

Publication Number Publication Date
CA2210396A1 true CA2210396A1 (fr) 1995-07-20

Family

ID=23473920

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002210396A Abandoned CA2210396A1 (fr) 1995-01-17 1995-01-17 Procede de detection et de traitement du cancer du sein

Country Status (3)

Country Link
EP (1) EP0804453A4 (fr)
AU (1) AU707348B2 (fr)
CA (1) CA2210396A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE201445T1 (de) * 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504095A (ja) * 1992-09-18 1996-05-07 カンジ，インコーポレイテッド 腫瘍抑制遺伝子を有するレトロウイルスベクターによる遺伝子療法
WO1994016080A1 (fr) * 1993-01-08 1994-07-21 Exemplar Corporation Procede in vitro/in vivo d'identification de medicaments anti-neoplasiques
ATE201445T1 (de) * 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens

Also Published As

Publication number Publication date
AU1831795A (en) 1995-08-01
EP0804453A1 (fr) 1997-11-05
EP0804453A4 (fr) 2004-08-11
AU707348B2 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
US6342483B1 (en) Method for detection and treatment of breast cancer
US7807373B2 (en) Prostate specific gene, PCGEM1, and methods of using PCEGM1 to detect, treat, and prevent prostate cancer
Mok et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer
US5677125A (en) Method of detection and diagnosis of pre-invasive cancer
Su et al. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family.
EP0711173B1 (fr) Peptides isoles formant des complexes avec la molecule mhc du clone hla-c 10 et utilisation de ceux-ci
Matsumura et al. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities
JP2009165492A (ja) ガンについてのマーカーである、ラビリンチンをコードする遺伝子
EP1185639B1 (fr) Gene prostatique specifique, famille de genes pcgem1, et methodes d'emploi de pcgem1 pour la detection, le traitement et la prevention du cancer de la prostate
JP2002541805A (ja) 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
JP4982869B2 (ja) Ｌｍｐ２を用いた子宮平滑筋肉腫の検出
Burger et al. Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12
US5830646A (en) Diagnostic method
CA2210396A1 (fr) Procede de detection et de traitement du cancer du sein
JP2002503096A (ja) 腫瘍拒絶抗原前駆体ｍａｇｅ−ｃ１およびｍａｇｅ−ｃ２をコードする単離核酸分子とその利用方法
US7776519B2 (en) Use of the slug gene, or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
JPH09504682A (ja) 腫瘍転移遺伝子
EP1072687A2 (fr) Méthode pour analyser le potentiel métastatique et méthode pour cribler des substances ayant une activité supprimant les métastases
Müller-Pillasch et al. Cloning of novel transcripts of the human guanine-nucleotide-exchange factor Mss4: In SituChromosomal mapping and expression in pancreatic cancer
Dawkins et al. nm23-H1 metastasis suppressor gene expression in primary breast cancer: associations with axillary lymph node status, tumour size, type and grade
US20040058337A1 (en) Process for determining the tumorcidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells
Liu Isolation of candidate genes related to human tumor invasiveness from breast cancer cell lines by mRNA differential display
US20030138799A1 (en) Oncogene identification by transformation of RK3E cells and uses thereof
Zendman Differentially expressed genes during human cutaneous melanocytic tumor progression: a focus on cancer/testis-associated genes
CA2271326A1 (fr) Gene dtf-a, methode de diagnostic et utilisations therapeutiques connexes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead